A5064466179- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Uterine Myomas and Treatments
- Cell Adhesion Molecules Research
- Endometriosis Research and Treatment
- Chromatin Remodeling and Cancer
- Protein Degradation and Inhibitors
- Cancer-related molecular mechanisms research
- BRCA gene mutations in cancer
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Circular RNAs in diseases
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Advanced Radiotherapy Techniques
- MicroRNA in disease regulation
- Management of metastatic bone disease
- Sarcoma Diagnosis and Treatment
Università Cattolica del Sacro Cuore
2018-2023
Agostino Gemelli University Polyclinic
2021-2022
Yale University
2020-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2019
Gynecologic Oncology Group
2019
University of the Sacred Heart
2019
Recurrence of endometrial cancer is an important clinical challenge, with median survival rarely exceeding 12 months. The aim this study was to analyze patterns recurrence and associations these outcome.The included patients who underwent primary surgical treatment or without adjuvant between July 2004 June 2017 at the Gynaecologic Oncology Unit one three tertiary hospitals Catholic University Network in Italy complete follow-up data available. Information on date pattern retrieved for each...
Background Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, active metabolite of irinotecan. This study aimed evaluate Trop-2 expression EOC tissues and preclinical activity SG against primary lines xenografts. Methods was assessed 90 formalin-fixed-paraffin-embedded tumors...
The integration of molecular features with clinicopathological findings in endometrial cancer classification seems to be able significantly refine risk assessment. Nevertheless, clinical management remains challenging, and different therapeutic options are available for each class. Further prognostic characterization the subgroups within class could helpful decision-making process.This study evaluated role 2020 European Society Gynaecological Oncology (ESGO)/European Radiotherapy...
Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, combination with carboplatin/paclitaxel, considered the preferred regimen for treatment advanced or recurrent HER2/Neu+ USC per NCCN guidelines.We describe two patients overexpression at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplification fluorescence situ hybridization (FISH) assay that,...
In endometrial carcinoma, both L1CAM overexpression and microcystic, elongated fragmented (MELF) patterns of invasion have been related to epithelial-to-mesenchymal transition metastatic spread. We aimed assess the association between expression, MELF pattern, lymph node status in carcinoma. Consecutive cases carcinoma with pattern were immunohistochemically assessed for L1CAM. Inclusion criteria endometrioid-type, low-grade, stage T1, known status. Uni- multivariate logistic regression used...
Objectives: Sentinel lymph node biopsy is considered a crucial step in endometrial cancer staging. Cervical injection has become the most favored technique and indocyanine green been demonstrated to be more accurate than other tracers. Different near-infrared camera systems are currently being used detect sentinel nodes have compared different patients. The present study aimed determine number site of detected same patients with two technologies. Methods: This prospective, single-center,...
Abstract Purpose: The prognosis for women with advanced or recurrent cervical cancer (CC) no longer responsive to radiation and/or chemotherapy remains poor. Whole-exome-sequencing (WES) studies have recently reported c-MYC gene amplification and HUWE1 mutations in a significant number of CC suggesting the HUWE1/c-MYC pathway as potential therapeutic target. We investigated expression fresh-frozen activity novel BET bromodomain inhibitor GS-626510 (Gilead-Science-Inc.) against primary WES...
<h3>Introduction</h3> The implementation of cancer molecular characterization in clinical practice has improved prognostic re- definition extending the eligibility to a continuous increasing number targeted treatments. A based primary tumor agnostic approach, could satisfy this purpose. Although 2020 European Society Medical Oncology recommended comprehensive genomic profiling (CGP) at least academic centers many challenges have be acknowledged. <h3>Methods</h3> In present monocentric...
Abstract Objective: Uterine serous carcinoma (USC) is an aggressive histologic variant of endometrial cancer which portends a poor prognosis. DHES0815A novel antibody-drug-conjugate (ADC) binds specifically to HER2 overexpressing tumors at distinct epitope from that bound by trastuzumab and pertuzumab after it delivers the toxic payload, PBD-MA, DNA mono-alkylating agent. The objective this study was evaluate preclinical activity against primary USC cell lines xenografts. Methods: Twelve...